Unilife announced the signing of a long-term supply contract with Sanofi after pharma deals with the big pharma company.
Unilife has agreed pharma deals to supply Sanofi with the Unifill Finesse, a customized device from its Unifill platform of prefilled syringes with automatic, needle retraction, for use with the anti-thrombotic therapy Enoxaparin Sodium sold under the brand names Lovenox and Clexane.
The pharma deals contract period can extend up to 2024.
Unilife has granted Sanofi the exclusive use of the Unifill Finesse with anti-thrombotic drugs during the pharma deals contract period.
Following a four year ramp-up period after market entry, exclusivity will be maintained, subject to Sanofi purchasing a minimum of 150 million units of the Unifill Finesse or other Unifill syringes per year.
Unilife can supply its Unifill syringes, including the Unifill Finesse, to additional customers in all other therapeutic classes outside of anti-thrombotics.
In addition to future revenue from the sale of Unifill Finesse syringes, Unilife may receive up to $15 million from Sanofi in milestones based payments with $5 million of these payments expected in 2013 as part of the pharma deals.
The supply pharma deals replaces and supersedes all other agreements previously signed between both parties regarding the Unifill syringe platform.
For commercial purposes and due to confidentiality clauses in the Agreement, additional terms of the pharma deals are to remain confidential.
Report: Partnering Deals and Alliances with Sanofi
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity